Mehta Vimal 4

What Happened
Vimal Mehta, CEO, President and a director of BioXcel Therapeutics (BTAI), reported converting a total of 383 derivative awards into common shares via two exercises/conversions: 164 shares on March 14, 2026 and 219 shares on March 15, 2026. The filing shows $0 cash consideration for the conversions (reported as derivative exercises), indicating RSUs/derivatives were converted into shares rather than sold for cash.

Key Details

• Transaction dates: March 14, 2026 (164 shares) and March 15, 2026 (219 shares) — total 383 shares converted.
• Reported price/value: $0.00 reported on the disposition lines for the derivative conversion; acquisition price listed as N/A. No cash proceeds reported.
• Filing: Form 4 filed March 16, 2026 for transactions occurring March 14–15 (filed timely).
• Shares owned after transaction: not specified in the filing.
• Footnotes of note:
  • F1: Each RSU represents a contingent right to receive one share of common stock.
  • F2: Some securities are held of record by BioXcel LLC (a subsidiary of BioXcel Holdings); Mr. Mehta may be deemed to beneficially own those shares due to his roles, but he disclaims beneficial ownership except to the extent of any pecuniary interest.
  • F3/F4: The reported RSUs stem from grants on Mar 14, 2022 (2,609 RSUs) and Mar 15, 2023 (3,500 RSUs) with multi-year vesting schedules — the conversions likely reflect vested portions of those grants.

Context
This filing documents conversion/exercise of restricted stock units (derivative awards) into common shares, not an open-market sale or purchase. Conversions like this typically reflect vesting and the issuance of shares rather than a buy/sell decision; they do not by themselves signal a bullish or bearish view.